Baxter Appoints Todd Young as Treasurer and Corporate Officer

Baxter Appoints Todd Young as Treasurer and Corporate Officer

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) announced today that its Board of Directors has elected Todd S. Young as treasurer and a corporate officer of the company.

Young will report to Baxter's chief financial officer, Robert Hombach, succeeding James K. Saccaro in the role. Saccaro has assumed a senior leadership role within the company's Medical Products commercial organization.

In his previous role, Young served as vice president, international finance for Baxter. He joined the company in 2001 as corporate tax counsel, and over the years assumed positions of increasing responsibility, including vice president of international tax, assistant treasurer, vice president, finance for the company's Asia Pacific region, and vice president, corporate planning and analysis. Prior to joining Baxter, he worked as a tax attorney at Sidley & Austin. Originally from Hiawatha, Kansas, Young earned his bachelor's degree in economics from Grinnell College and his law degree from the University of Michigan.

Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.

Contacts

Baxter International Inc.
Media Contact:
Deborah Spak, (224) 948-2349
or
Investor Contact:
Mary Kay Ladone, (224) 948-3371

Suggested Articles

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.

The decision to dump IL33r antagonist GSK3772847 follows lackluster clinical data on rival candidates against the same target.